The UK-Slovak Sensible Biotechnologies gets $4.2M to develop mRNA therapeutics and vaccines

Sensible Biotechnologies, a mRNA platform company, has received a $4.2 million pre-seed round to accelerate the development of its cell-based platform. The round was led by BlueYard Capital.

• Sensible Biotechnologies is a biotechnology company that was founded by Miroslav Gasparek and Marian Kupculak in 2021. The company is based in Oxford, and has a biomedical research center in Bratislava. 
• Sensible Biotechnologies builds a cell-based platform for the production of high-quality mRNA. The platform eliminates the major bottlenecks in the mRNA production process in an effort to unlock the full potential of mRNA technology for the next generation of therapeutics and vaccines. 

“This funding will enable us to advance the development of our cell-based mRNA manufacturing platform and to unlock the full potential of mRNA technology in life-saving therapies, while strengthening the robustness of the mRNA supply chain,”

said Miroslav Gasparek, the CEO and co-founder of Sensible Biotechnologies.

• The pre-seed round was led by Berlin-based VC fund BlueYard Capital, with participation from US accelerator Y Combinator, German’s early stage venture firm Amino Collective, California-based VC firms Civilization Ventures and Recode Health Ventures, and Czech ZAKA VC that has recently joined a $2.5 million seed round for the UK fintech Prograd.
• Sensible Biotechnologie will use the fresh funding to accelerate the development of its mRNA manufacturing platform.